Volume 7, Issue 12 , Pages 1279-1286, December 2009
Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis
Full Text Available
Conflicts of interest The authors disclose the following: Nicholas Talley has received consultancy fees from Procter and Gamble, Lexicon Genetics, Inc, Astellas Pharma US, Inc, Pharma Frontiers, Ltd, Callisto Pharmaceuticals, AstraZeneca, Addex Pharma, Ferring Pharma, Salix, MGI Pharma, McNeil Consumer, Microbia, Dynogen, Conexus, Novartis, and Metabolic Pharmaceuticals, and has received research support from Novartis, Takeda, GlaxoSmithkline, Dynogen, and Tioga; Paul Moayyedi is the chair at McMaster University and is funded partly by an unrestricted donation by AstraZeneca, and has received consultant's and speaker's bureau fees from AstraZeneca, AxCan Pharma, Nycomed, and Johnson and Johnson. The remaining authors disclose no conflicts.
Funding This study was funded by the American College of Gastroenterology.
PII: S1542-3565(09)00660-0
doi:10.1016/j.cgh.2009.06.031
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.
Refers to article:
-

Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report
, 25 August 2009
Volume 7, Issue 12 , Pages 1279-1286, December 2009


